4//SEC Filing
Chappell Todd 4
Accession 0000950170-23-060607
CIK 0001703647other
Filed
Nov 6, 7:00 PM ET
Accepted
Nov 7, 9:14 PM ET
Size
15.2 KB
Accession
0000950170-23-060607
Insider Transaction Report
Form 4
Korro Bio, Inc.KRRO
Chappell Todd
Chief Operating Officer
Transactions
- Award
Stock Option (Right to Buy)
2023-11-03+5,128→ 5,128 totalExercise: $20.94Exp: 2033-01-23→ Common Stock (5,128 underlying) - Award
Stock Option (Right to Buy)
2023-11-03+13,625→ 13,625 totalExercise: $11.68Exp: 2031-03-09→ Common Stock (13,625 underlying) - Award
Stock Option (Right to Buy)
2023-11-03+4,968→ 4,968 totalExercise: $22.75Exp: 2032-01-26→ Common Stock (4,968 underlying) - Award
Stock Option (Right to Buy)
2023-11-03+62,651→ 62,651 totalExercise: $14.98Exp: 2033-11-02→ Common Stock (62,651 underlying)
Footnotes (9)
- [F1]Under the terms of an Agreement and Plan of Merger dated as of July 14, 2023 by and among Korro Bio Ops, Inc. (f/k/a Korro Bio, Inc., "Legacy Korro"), the Issuer (f/k/a Frequency Therapeutics, Inc.) and Frequency Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), on November 3, 2023, Merger Sub merged with and into Legacy Korro (the "Merger"), with Legacy Korro surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Korro common stock issued under the Korro Bio, Inc. 2019 Stock Incentive Plan (the "2019 Plan") was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, at an exchange ratio of 0.049688 per share, on the same terms and conditions as were applicable under the 2019 Plan prior to the Merger, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-50.
- [F2](Continued from footnote 1) Subsequent to the Merger, the name of the Issuer was changed from Frequency Therapeutics, Inc. to Korro Bio, Inc.
- [F3]The shares subject to the option vest as to 25% of the shares on March 8, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
- [F4]Received in exchange for a stock option to acquire 274,220 shares of Legacy Korro common stock issued under the 2019 Plan pursuant to the Merger Agreement.
- [F5]The shares subject to the option vest as to 25% of the shares on January 27, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
- [F6]Received in exchange for a stock option to acquire 100,000 shares of Legacy Korro common stock issued under the 2019 Plan pursuant to the Merger Agreement.
- [F7]The shares subject to the option vest as to 25% of the shares on January 1, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
- [F8]Received in exchange for a stock option to acquire 103,223 shares of Legacy Korro common stock issued under the 2019 Plan pursuant to the Merger Agreement.
- [F9]The shares subject to the option vest in 48 equal monthly installments commencing from November 3, 2023, subject to the Reporting Person's continued service on each such vesting date.
Documents
Issuer
Korro Bio, Inc.
CIK 0001703647
Entity typeother
Related Parties
1- filerCIK 0001997992
Filing Metadata
- Form type
- 4
- Filed
- Nov 6, 7:00 PM ET
- Accepted
- Nov 7, 9:14 PM ET
- Size
- 15.2 KB